Current Standard for High-risk Upper Tract Urothelial Cancer: Platinum-based Chemotherapy—Proven, Not Postulated
European Urology Focus · 2026
DOI: 10.1016/j.euf.2025.11.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Urology Focus, 2026. Verfasst von Alison J Birtle. Beteiligte Einrichtung: Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK. Electronic address: alison.birtle@lthtr.nhs.uk. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Ureteral Neoplasms, Kidney Neoplasms, Urologic Neoplasms. Die Arbeit nennt 10 Literaturangaben. Gefördert von: Cancer Research UK.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Adjuvant chemotherapy is the standard of care for high-risk upper tract urothelial carcinoma after radical nephroureterectomy. Level 1 data and global guidelines confirm that this is the case, and adjuvant chemotherapy remains the option to beat in this setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK. Electronic address: alison.birtle@lthtr.nhs.uk.
Förderung
- Cancer Research UK
Zitieren
APA
Birtle, A. J. (2026). Current Standard for High-risk Upper Tract Urothelial Cancer: Platinum-based Chemotherapy—Proven, Not Postulated. European Urology Focus. https://doi.org/10.1016/j.euf.2025.11.012
Vancouver
Birtle AJ. Current Standard for High-risk Upper Tract Urothelial Cancer: Platinum-based Chemotherapy—Proven, Not Postulated. European Urology Focus. 2026. doi:10.1016/j.euf.2025.11.012
BibTeX
@article{Birtle2026,
author = {Birtle, Alison J},
title = {Current Standard for High-risk Upper Tract Urothelial Cancer: Platinum-based Chemotherapy—Proven, Not Postulated},
journal = {European Urology Focus},
year = {2026},
doi = {10.1016/j.euf.2025.11.012}
}
EUVIMED